Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer.

Badiginchala, Revathi; Dattatreya, Palanki Satya; Suresh, Attili Venkata Satya; Nirni, Sharanabasappa Somanath; Andra, Vindhya Vasini; Bunger, Deepak; Chaturvedi, Alok

Badiginchala, Revathi; Dattatreya, Palanki Satya; Suresh, Attili Venkata Satya; Nirni, Sharanabasappa Somanath; Andra, Vindhya Vasini; Bunger, Deepak; Chaturvedi, Alok.

Afiliación

Badiginchala R; Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India.
Dattatreya PS; Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India.
Suresh AVS; Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India.
Nirni SS; Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India.
Andra VV; Medical Oncology, Omega Hospitals, Hyderabad, Telangana, India.
Bunger D; Medical Affairs, Intas Pharmaceuticals Limited, Ahmedabad, India.
Chaturvedi A; Medical Affairs, Intas Pharmaceuticals Limited, Ahmedabad, India.

Onco Targets Ther ; 16: 215-225, 2023.

Article en En | MEDLINE | ID: mdl-37033671

Palabras clave

NDLS; breast cancer; docetaxel; nanosomal docetaxel lipid suspension; operable

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Onco Targets Ther Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google